On average, tirzepatide produces more weight loss at maximum dose
Your GLP-1 weight loss might differ from someone else's each month, and that is completely fine
Phase 3 trials typically enroll thousands
Alejandra Tomas, [email protected] This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This review synthesizes current evidence regarding SGLT2 inhibitors and GLP-1 receptor agonists in DKD, examines their mechanisms and clinical outcomes, and highlights future research directions to address ongoing therapeutic needs
Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet